We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Cpt3.5

Captopril Research

Mostly mechanism / observationalLimited safety

5 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Captopril studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality randomised trials published 2003–2025.

Based on 5 studies · 1 RCT

Confidence

Low

By outcome

Lifespan & aging (model organisms)
Mostly mechanism / observational4 studies
Cardiovascular & renal
Too few graded studies1 study

Active research area

3 studies in the last 5 years

200320142025

1RCT2003

Captopril (and valsartan) reduced mortality and morbidity in myocardial infarction complicated by heart failure.

Pfeffer, McMurray, Velazquez, Rouleau, Køber, Maggioni · The New England journal of medicine (2003)

VALIANT randomized trial including a captopril arm in post-MI heart failure
ACE inhibition reduced cardiovascular mortality and morbidity
Landmark human outcome evidence for the class

View source

2Review2022

The renin-angiotensin system controls aging across C. elegans, Drosophila, and mammalian models.

Egan, Scharf, Pohl, Kornfeld · Frontiers in pharmacology (2022)

Review framing RAS/ACE modulation as a conserved aging pathway
Synthesizes lifespan/healthspan evidence across model organisms
Positions ACE inhibitors among candidate geroprotectors

View source

3Animal2016

An angiotensin-converting-enzyme inhibitor extended the lifespan of Caenorhabditis elegans.

Kumar, Dietrich, Kornfeld · PLoS genetics (2016)

ACE inhibition extended lifespan in the worm C. elegans
Implicates the renin-angiotensin system as a conserved aging pathway
Model-organism evidence underpinning the geroprotector hypothesis

View source

4Animal2024

The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging in C. elegans.

Egan, Pohl, Anderson, Williams, Gregory Adodo, Hunt · Development (Cambridge, England) (2024)

Captopril specifically inhibits the worm ACE homolog ACN-1
Modulates dauer formation and aging pathways in C. elegans
Provides a captopril-specific mechanism for the lifespan effect

View source

5Review2025

ACE inhibitors influence metabolic aging, as shown from a Drosophila perspective.

Vecchie', Faber, Jumbo-Lucioni, Anholt, Mackay, De Luca · Biomolecules (2025)

Review of ACE-inhibitor effects on metabolic aging in Drosophila
Extends the RAS-aging story to metabolic/insulin signaling
Reinforces cross-species geroprotective rationale

View source

View in Research Library

Captopril Research

Mostly mechanism / observational

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Control of aging by the renin-angiotensin system: a review of C. elegans, Drosophila, and mammals.

Angiotensin Converting Enzyme (ACE) Inhibitor Extends Caenorhabditis elegans Life Span.

The ACE inhibitor captopril inhibits ACN-1 to control dauer formation and aging.

Angiotensin-Converting Enzyme Inhibitors and Metabolic Aging: A Drosophila Perspective.